Announcements Trials
Browse Landscape

Phase

Phase 3 13Phase 2 5Phase 1 5Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Cisplatin 17Magnetic Resonance Spectroscopy 16Specimen Handling 13pembrolizumab 10Carboplatin 10Gemcitabine 9Paclitaxel 8Radiotherapy 7Radiation 7Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Pemetrexed 6Nivolumab 6Doxorubicin 6Surgical Procedures, Operative 5Radiotherapy, Intensity-Modulated 5Docetaxel 5Dexamethasone 5Biopsy 5atezolizumab 4Rituximab 4Immunoglobulin G 4Disulfides 4Bevacizumab 4Temozolomide 3Standard of Care 3Ramucirumab 3Drug Therapy 3Cyclophosphamide 3Cetuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Topotecan × 30 days × Clear all
NCT06161025 2026-05-22

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Daiichi Sankyo

Phase 2/3 Recruiting
860 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡